Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry
Open Access
- 16 February 2022
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 85 (Pt B) , 188-202
Abstract
No abstract availableKeywords
Funding Information
- Merck KGaA
This publication has 37 references indexed in Scilit:
- A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transferFertility and Sterility, 2012
- Probabilistic sensitivity analysis in health economicsStatistical Methods in Medical Research, 2011
- In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart reviewReproductive Biology and Endocrinology, 2010
- HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: success rates and economic evaluationReproductive BioMedicine Online, 2010
- Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alphaFertility and Sterility, 2009
- Cumulative Live-Birth Rates after In Vitro FertilizationNew England Journal of Medicine, 2009
- Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force ReportValue in Health, 2007
- What is the most relevant standard of success in assisted reproduction?Human Reproduction, 2004
- Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trialFertility and Sterility, 2002
- Follitropin Alpha in InfertilityBioDrugs, 1998